Acute atomoxetine treatment of younger and older children with ADHD: A meta-analysis of tolerability and efficacy

<p>Abstract</p> <p>Background</p> <p>Atomoxetine is FDA-approved as a treatment of attention-deficit/hyperactivity disorder (ADHD) in patients aged 6 years to adult. Among pediatric clinical trials of atomoxetine to date, six with a randomized, double-blind, placebo-con...

Full description

Bibliographic Details
Main Authors: Vaughan Brigette S, Milton Denái R, Kratochvil Christopher J, Greenhill Laurence L
Format: Article
Language:English
Published: BMC 2008-09-01
Series:Child and Adolescent Psychiatry and Mental Health
Online Access:http://www.capmh.com/content/2/1/25